{"entity":{"id":"vvkt-lithuania","kind":"institution","name":"State Medicines Control Agency under the Ministry of Health (VVKT)","aka":["Valstybinė vaistų kontrolės tarnyba","VVKT","State Medicines Control Service of Lithuania"],"tldr":"Lithuania's medicines regulator. Most new cancer medicines are authorised for the whole EU through the European Medicines Agency; in Lithuania VVKT also evaluates applications for a medicine to be reimbursed, and an audit in 2023 found a long backlog.","summary":"The State Medicines Control Agency (Valstybinė vaistų kontrolės tarnyba, VVKT) is Lithuania's national medicines authority, part of the European medicines regulatory network in which new cancer medicines are authorised centrally on the European Medicines Agency's opinion. The OECD and European Commission's Country Cancer Profile 2025 describes its role in reimbursement: VVKT evaluates applications and makes recommendations, after which the Medicinal Products and Medical Aid Reimbursement Commission decides whether a medicine joins the reimbursable list. The coordinates are an approximate Vilnius city point.\n\nQuoting the State Audit Office's 2023 audit of medicine availability, the profile reports that of 140 new drug applications made since January 2020, 60 had received a decision from VVKT by 12 September 2023, of which 8 met the 180-day limit set by the EU Transparency Directive; 66 applications were pending, with waits of between 223 and 902 days. In 2022 the number of specialists assessing new drug applications rose from eight to ten. The profile gives a mean of 1,141 days between European approval and a reimbursement decision for new cancer medicines in Lithuania, the second longest of 22 EU countries with data.\n\nVVKT's own site, vvkt.lrv.lt, answered a plain request with a bot challenge on 11 November 2026 and was not read for this record.","asOf":"2026-11-11","links":[{"label":"OECD and European Commission: EU Country Cancer Profile Lithuania 2025, section 5.1 (PDF, Internet Archive copy)","url":"https://web.archive.org/web/20260519070348/https://cancer-inequalities.jrc.ec.europa.eu/sites/default/files/docs/ccp2025/ec-oecd-lt-2024-1674-en.pdf"},{"label":"EU Country Cancer Profile Lithuania 2025 (OECD record)","url":"https://doi.org/10.1787/b260e7d1-en"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lithuania-ministry-of-health","ema"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vilnius","country":"LT","lat":54.7,"lng":25.3,"institutionType":"government","website":"https://vvkt.lrv.lt","programs":["National marketing authorisation of medicines","Evaluation of reimbursement applications","Part of the European medicines regulatory network"]},"route":"/institutions/vvkt-lithuania/","neighbours":{"institution":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/"},{"id":"lithuania-ministry-of-health","kind":"institution","name":"Ministry of Health of the Republic of Lithuania","route":"/institutions/lithuania-ministry-of-health/"},{"id":"vlk-lithuania","kind":"institution","name":"National Health Insurance Fund under the Ministry of Health (VLK)","route":"/institutions/vlk-lithuania/"}]}}